In this section
In this subsection

Cipla Tadalafil Products

Cipla is associated with several tadalafil products, but they do not all represent the same indication or market. Current U.S. records include Cipla tadalafil products in the Cialis-reference generic category for erectile dysfunction and benign prostatic hyperplasia, while a separate 20 mg Cipla product is labeled for pulmonary arterial hypertension. In Australia, Tadacip is a Cipla-sponsored tadalafil brand with its own current registration and supply history.

This makes exact product identification essential. Searching “Cipla tadalafil,” “Cipla Cialis generic,” “Tadacip,” or “Cipla 526” can lead to different products even though tadalafil is the shared active ingredient.

Tadalafil as an Active Ingredient

Tadalafil is a PDE5 inhibitor used in prescription medicines. In the United States, Cialis-reference tadalafil products can be labeled for erectile dysfunction, benign prostatic hyperplasia, or both. A separate tadalafil product category references Adcirca and is labeled for pulmonary arterial hypertension.

The active ingredient alone therefore does not determine the indication. A 20 mg tadalafil tablet can belong to an ED/BPH product family or to a PAH product family. The regulatory record, product identifier, and accompanying label are what distinguish them.

Cipla Tadalafil Products and Brand Names

Current records support several different Cipla relationships:

  • Cipla USA tadalafil tablets in the Cialis-reference generic family, with source NDCs in the 69097-373 through 69097-376 series;
  • a separate Cipla USA 20 mg tadalafil product under NDC 69097-526, labeled for pulmonary arterial hypertension;
  • Tadacip products sponsored by Cipla Australia Pty Ltd in Australia.

These should not be collapsed into a single “Cipla tadalafil” listing. The U.S. generic name may simply be tadalafil, while Tadacip is a market-specific brand name, and “Cipla 526” refers to a tablet marking and NDC fragment tied to a specific PAH product.

Cipla Tadalafil in the United States

DailyMed currently lists a Cipla USA tadalafil family with 2.5 mg, 5 mg, 10 mg, and 20 mg strengths associated with the Cialis-reference generic category. Current labeling for that category covers erectile dysfunction, benign prostatic hyperplasia, and ED/BPH depending on the prescribed use.

A separate Cipla USA DailyMed record covers tadalafil 20 mg under NDC 69097-526 and ANDA 210255. That product is labeled for pulmonary arterial hypertension, not as a Cialis-reference ED product. The tablet description in the current label states that it is marked “Cipla” on one side and “526” on the other.

The current label confirms that “Cipla 526” identifies a tadalafil product, but the product context is specific: Cipla 526 is associated with a PAH-labeled 20 mg tadalafil product. It should not be presented as an ED product or suggested as a substitute for an ED/BPH tadalafil prescription.

Tadacip is a Cipla-associated tadalafil brand documented in Australia, with strength-specific regulatory and supply records that have changed over time. See the Tadacip by Cipla guide for the current Australian status by strength and a comparison with Cipla’s U.S. generic tadalafil products.

Strengths, Forms and Indications

Current U.S. Cipla Cialis-reference tadalafil records include 2.5 mg, 5 mg, 10 mg, and 20 mg film-coated tablets. These belong to the ED/BPH product family. The exact strength dispensed is determined by the prescription and labeling; this reference page does not provide individualized dosing instructions.

The separate U.S. Cipla NDC 69097-526 product is a 20 mg film-coated tablet for PAH. Even though 20 mg is also seen in ED/BPH tadalafil product families, the indication and product identity are different.

Australian Tadacip records include multiple tablet strengths as well, but current supply and registration status vary by strength. That market-specific status should be checked before treating an old strength list as current availability.

What the “Cipla 526” Marking Actually Identifies

The “Cipla 526” marking can now be verified directly from a current label. DailyMed describes the NDC 69097-526 tadalafil tablet as a brown, capsule-shaped 20 mg tablet with “Cipla” on one side and “526” on the other. The same record identifies the product under ANDA 210255 and labels it for pulmonary arterial hypertension.

That means the imprint is useful for product identification but should not be used as shorthand for “Cipla Cialis” or “Cipla ED tablet.” A different Cipla tadalafil family uses source NDCs 69097-373 through 69097-376 and belongs to the Cialis-reference ED/BPH category. Two Cipla tablets can therefore share tadalafil as the ingredient while belonging to different regulatory and clinical product families.

Tadacip as an Example of Changing Market Status

Tadacip also shows why a product page needs a date-sensitive market check. Australian TGA records verify Cipla Australia as sponsor of multiple Tadacip tadalafil registrations, but the strength-specific status has changed over time. The 2.5 mg registration was cancelled in 2025, and 2026 shortage information shows the 10 mg product moving through discontinuation with supply being exhausted.

At the same time, Australian government and Healthdirect records can still surface Tadacip as a known tadalafil brand. A familiar or widely referenced product name therefore does not necessarily indicate current routine supply. A buyer or pharmacist should check the exact strength and current regulator/supply status rather than treating an old product family as uniformly active.

How to Verify a Cipla Tadalafil Product

For a U.S. package, match the strength and NDC to the current DailyMed record and check the indication section. For an Australian Tadacip package, match the ARTG entry, sponsor, strength, and current supply status. If a product is offered under a different country’s label, use that country’s regulator rather than assuming the U.S. or Australian record applies.

This is particularly important for 20 mg tadalafil because both ED/BPH and PAH product families can use that strength. Strength alone is not enough to decide which label applies.

Regulatory Status and Market Availability

For U.S. tadalafil, DailyMed and FDA application records provide product-specific information. The presence of Cipla USA tadalafil under an ANDA verifies those U.S. generic products. It does not make every Cipla tadalafil brand from another country an FDA-approved U.S. product.

For Australia, the TGA provides the relevant product registration and shortage/discontinuation information. Tadacip’s Australian status should therefore be described using Australian records rather than a U.S. database.

Availability at a pharmacy is still a separate question. An active regulatory record is not a guarantee of local stock, and a discontinued or supply-limited product may remain easy to find in search results. This page does not claim current Paulsen’s Pharmacy inventory.

Comparing Cipla Tadalafil Products

A useful comparison should distinguish at least the following:

  • active ingredient: tadalafil;
  • strength: 2.5 mg, 5 mg, 10 mg, or 20 mg where verified;
  • form: currently verified examples are oral film-coated tablets;
  • indication: ED/BPH versus PAH is a critical distinction;
  • brand or generic identity: generic tadalafil, Tadacip, and the Cipla 526 PAH product are not the same product label;
  • market: United States and Australia have different product records;
  • regulatory identifier: NDC/ANDA in the U.S. or ARTG registration in Australia.

That comparison is more reliable than using a single product name as shorthand. In particular, the Cipla 526 imprint should not be interpreted as evidence that the tablet is the ED/BPH version of tadalafil.

When a package is being compared against a search result, the imprint should be treated as one identifier among several. A matching strength, NDC or registration number, manufacturer, indication, and current label provide a much stronger product match than the imprint alone.

More About Cipla

For company-level information and navigation to Cipla’s wider portfolio, see Cipla Limited. Users comparing another PDE5 inhibitor from the same manufacturer can also review Cipla sildenafil products.

The two ingredient pages serve different search questions. Sildenafil and tadalafil have different product families, labels, strengths, and market-specific brand histories even when the same manufacturer is involved.

Reviewed by: Dr. Nancy Ann Curosh